20 results about "Gene carrier" patented technology

The invention discloses a dihydrodaidzein reductase, a combinatorial enzyme and an application of the dihydrodaidzein reductase and the combinatorial enzyme in synthesis of S-equol. The dihydrodaidzein reductase is a mutant which takes the dihydrodaidzein reductase AeDHDR as a starting sequence and has a corresponding mutation site, wherein the dihydrodaidzein reductase AeDHDR is derived from AdleCRzia equaliforns, and the amino acid sequence of the dihydrodaidzein reductase AeDHDR is shown as SEQ ID NO: 2. The invention also discloses a coding gene, a carrier and a bioengineering bacterium of the dihydrodaidzein reductase mutant and a method for synthesizing S-equol. The method has the advantages of high enzyme activity and high S-equol yield.

The application discloses a mucous membrane adhesion auxiliary material and a lipid material with mucous membrane adhesion prepared by using the auxiliary material, the nanoparticle has mucous membrane adhesion and can be adhered to the surface of a mucous membrane and is suitable for mucous membrane administration. The lipid nanoparticle promotes the entry of the lipid nanoparticle into cells by forming a disulfide bond with the sulfydryl on the surface of mucous membrane cells, and the entry of the lipid nanoparticle into cells is a non-endosome-lysosome pathway, so that the encapsulated nucleic acid macromolecule can be avoided from being degraded by enzymes in cells, thereby directly delivering the macromolecular nucleic acid in the cytoplasm to play a role.

In the field of gene therapy, a major hurdle is the design and identification of constructs and gene therapy vectors providing therapeutic effects while displaying satisfactory safety profiles. In the treatment of Diamond-Blackfan Anemia (DBA), therapies alleviating several crucial anemia symptoms, such as blood or bone marrow cellularity, hemoglobin levels, erythrocytes levels, or platelet levels, while showing satisfactory safety profiles remain a challenge. The present invention provides constructs encoding ribosomal protein genes involved in DBA, such as genes encoding RPS19, RPS17, RPS24, RPS10, RPL35a, RPL11, RPS26, and RPL5, vectors, methods, cells, and medical uses thereof, addressing these challenges and finding particular applications in the field of autologous cell therapy treatment of DBA. Further, the present invention provides a non-genotoxic conditioning protocol for preparing a subject prior to cell therapy treatment for DBA using construct of the present invention.

The invention relates to an organ selective regulation and control method of an ionizable lipid gene vector, which comprises the following steps: firstly, synthesizing uncoordinated ionizable lipid containing a ligand unit (such as cyclic amine), and forming ionizable lipid with different structural characteristics by selecting different tail chains, so that the ionizable lipid can directionally select liver or spleen; and metal ions are introduced into the non-coordinated ionizable lipid structure for coordination, so that the lung can be directionally selected. According to the method, nucleic acid molecules can be controllably and efficiently delivered to the liver, spleen or lung of a mouse, the method has the advantages of being simple, easy to implement and wide in universality, metal ion-ligand interaction is introduced into an uncoordinated ionizable lipid structure, charge distribution and apparent pKa of lipid nano particles are changed, and therefore the nucleic acid molecules can be efficiently and controllably delivered to the liver, spleen or lung of the mouse. The lipid nanoparticle organ is selectively converted from the liver or spleen to the lung, and ultrahigh nucleic acid molecule delivery efficiency is shown.

This invention provides an Alzheimer's disease risk assessment system, comprising: a data acquisition module for acquiring test data of subjects, the test data including at least the concentration of Aβ oligomers, APOEε4 gene carrier status data, and multi-domain risk factor data; the multi-domain risk factor data including demographic indicators and clinical data related to Alzheimer's disease risk; a risk assessment module, communicatively connected to the data acquisition module, for taking the test data from the data acquisition module as input, and outputting a risk probability value of the subject having Alzheimer's disease through a pre-trained machine learning model; and a result output module, communicatively connected to the risk assessment module, for comparing the risk probability value with a preset threshold and outputting risk classification information based on the comparison result. This invention is the first to achieve high-precision and high-sensitivity clinical cognitive impairment screening by fusing multidimensional conventional data through a nonlinear model.

The application provides a multifunctional shell material HPSO and a preparation method and application thereof, and belongs to the field of biological medicine. The structure of the multifunctional shell material HPSO is shown in formula I. After the HPSO is combined with a cationic polymer gene carrier, the positive charge of the cationic polymer gene carrier can be shielded, so that the gene carrier has a negative charge. The gene carrier with the negative charge can be used for in-vivo treatment through intravenous injection, and the problem of strong toxic side effects such as hemolysis caused by the combination of the existing cationic polymer gene carrier and negative proteins in blood is overcome. Meanwhile, the transfection efficiency of the cationic polymer gene carrier is not reduced after being combined with the shell material. In addition, the non-viral shell material HPSO can enhance the immune activation effect. The shell material HPSO has a good application prospect in the preparation of a gene carrier for in-vivo treatment. Formula I

The invention discloses a methyltransferase mutant as well as a coding gene, a vector, recombinant bacteria and application thereof, and belongs to the technical field of enzyme engineering. According to the invention, variants EgtDT163G, M252V and E282A of methyltransferase EgtD from M. smegmais ATCC700084 are mutated, Pro at the 35 site is mutated into Cys, Lys at the 36 site is mutated into Arg, Phe at the 38 site is mutated into Leu, Thr at the 168 site is mutated into Phe, the methylation catalytic efficiency with L-tryptophan as a substrate is obviously improved, and the L-erythrinine is efficiently synthesized. On the basis that the L-erythrinine is synthesized by using E. coli whole cells, a further theoretical and technical basis is provided for establishing an industrial production process of the L-erythrinine, which is low in production cost, high in production intensity and small in environmental pollution.

The present invention relates to a microstructure for the prevention and treatment of obesity and obesity-derived type 2 diabetes, comprising a complex of a gene and an adipocyte-targeting gene carrier. Being capable of suppressing the expression of FABP4 and FABP5 with the gene and the adipocyte-targeting gene carrier, the present invention can exhibit excellent prophylactic and therapeutic effects on obesity and obesity-derived type 2 diabetes.

The present invention relates to a gene carrier including a nucleic acid molecule containing a gene of interest conjugated to the surface of a metal nanoparticle, which is delivered into cells and expressed, a use thereof, a gene expression method using the same, and a method of preparing the same.

The invention discloses an endoglucanase mutant, a coding gene, a carrier, an engineering bacterium and application of the endoglucanase mutant. The endoglucanase mutant Egl is obtained by mutating the 124 amino acid and the 328 amino acid of wild type endoglucanase Egl from lysine and glutamic acid into arginine and lysine respectively, and mutating the 226 amino acid and the 269 amino acid from valine into cysteine; a mutant amino acid sequence and a nucleotide sequence of the gene are respectively SEQ ID NO. 1 and SEQ ID NO. 2. Under the conditions that the temperature is 50 DEG C and the pH value is 6.0, the specific enzyme activity of the mutant endoglucanase Egl is 6098.5 U / mg and is 3.1 times that of the wild endoglucanase Egl; the residual enzyme activity of the endoglucanase mutant Egl is 5302.9 U / mL and is 5.7 times that of a wild type when the temperature is kept at 70 DEG C for 40 minutes, so that the endoglucanase mutant Egl has an important application prospect under a weak acid condition.

The invention belongs to the technical field of drug carriers, and particularly relates to a hyaluronic acid and folic acid double-target-head modified cationic safflower polysaccharide nano-carrier as well as a preparation method and application thereof. The preparation method comprises the following steps: selecting cationic safflower polysaccharide (SPS-PEI) as a basic carrier, preparing self-assembled nanoparticles (Nanoparticles, NPs) by combining with siRNA through an electrostatic adsorption effect, covalently binding hyaluronic acid (HA) and folic acid (FA) through an esterification reaction to form a polymer, and coating the SPS-PEI with the polymer to construct the dual targeting nano gene carrier (HA-FA-SPS-PEI Nanoparticles, HFSPNPs). Research results show that compared with self-assembled single-target-head nanoparticles and target-head-free nanoparticles, the double-target-head nanoparticles siBMP2 / HFSPNPs disclosed by the invention have relatively strong tumor targeting property, and can be more effectively accumulated in tumor tissues and release siBMP2, so that expression of BMP2 protein is reduced, apoptosis of liver cancer cells is promoted, and the purpose of gene therapy is achieved.

The invention discloses a xylanase mutant Xyn, a coding gene, a carrier, an engineering bacterium as well as a preparation method and application. The xylanase mutant Xyn is obtained by mutating the 56th amino acid, the 152nd amino acid and the 204 amino acid of wild type xylanase Xyn into isoleucine, aspartic acid and glutamic acid from valine, asparagine and lysine respectively; the amino acid sequence and the nucleotide sequence of the gene are SEQ ID NO.1 and SEQ ID NO.2 respectively. Under the conditions that the pH is 10.0 and the temperature is 60 DEG C, the specific enzyme activity of the xylanase mutant Xyn is 9951.5 U / mL and is 2.2 times that of wild enzyme Xyn; after the xylanase mutant Xyn is subjected to heat preservation at 70 DEG C for 40 minutes, the residual enzyme activity of the xylanase mutant Xyn is 8312 U / mL, which is 4.1 times of that of wild enzyme Xyn, so that the xylanase mutant Xyn has important application prospects under alkaline conditions.

The invention discloses a ormosine methyltransferase mutant as well as a coding gene, a vector, recombinant bacteria and application thereof, and belongs to the technical field of enzyme engineering. According to the invention, mutagenesis is carried out on variants EgtDM252V and E282A of methyltransferase EgtD from M. smegmais ATCC700084, Pro at the 34 site is mutated into Lys, Thr at the 213 site is mutated into Ser, Ser at the 284 site is mutated into Ala, the methylation catalytic efficiency with L-ormosin as a substrate is obviously improved, and the L-erythrinine is efficiently synthesized. On the basis that the L-erythrinine is synthesized by using E. coli whole cells, a further theoretical and technical basis is provided for establishing an industrial production process of the L-erythrinine, which is low in production cost, high in production intensity and small in environmental pollution.

This invention discloses a method for preparing targeted magnetic microspheres with a bilayer structure and their applications, belonging to the fields of biomaterials and medical technology. Magnetic particles, dimethyloctadecyl[3-trimethoxysilylpropyl]ammonium chloride, 1,2-dioleoyl-sn-glycerol-3-phosphocholine, carboxymethyl chitosan hexadecyl quaternary ammonium salt, phospholipid-polyethylene glycol-amino group, and cholesterol are added to dichloromethane, and an emulsification reaction is carried out under ultrasonic conditions to obtain magnetic microspheres. Targeted magnetic microspheres can be prepared by adding antibodies or peptides after reaction. These targeted magnetic microspheres can be used in protein purification, nucleic acid extraction and separation, in vitro target cell sorting, in vivo target cell enrichment, targeted drug delivery, exosome sorting, drug delivery, drug carriers, targeted drug therapy, gene drug delivery, gene carrier construction, and magnetic resonance imaging contrast agents. The targeted magnetic microspheres have a bilayer structure, are positively charged, and exhibit superparamagnetism, biocompatibility, and safety.

The invention belongs to the technical field of biology, and relates to application and a method of a GmZTLa gene in regulation and control of recent rhythm of soybeans. The GmZTLa gene disclosed by the invention comprises two homologous copies, namely, GmZTLa1 (Glyma. 15G162300) and GmZTLa2 (Glyma. 09G056100), and is characterized in that the GmZTLa1 gene and the GmZTLa2 gene can be used as a gene carrier; according to the research of the invention, two GmZTLa genes in soybean are knocked out, and a delayed phenotype appears in a recent rhythm period. The CRISPR / Cas9 knockout technology constructed by the invention can obtain pure and gmztla1 / a2 mutant soybean plants, and compared with control soybeans, the CRISPR / Cas9 knockout technology obviously delays the recent rhythm of soybeans, and can be applied to breeding of soybeans suitable for multi-latitude region growth. The method has a huge application prospect.

This invention provides a multifunctional shell material PNP, its preparation method, and its applications, belonging to the field of biomedicine. The structure of the PNP shell material of this invention is shown in Formula I. When the multifunctional shell material PNP of this invention is combined with a cationic polymer gene carrier carrying a gene, it can shield the positive charge, making the gene carrier negatively charged. The negatively charged gene carrier can be used for in vivo treatment via intravenous injection, overcoming the problem of existing cationic polymer gene carriers binding to negatively charged proteins in the blood, causing hemolysis and other strong toxic side effects; simultaneously, the transfection efficiency of the cationic polymer gene carrier is not reduced after being combined with this shell material. The PNP shell material of this invention has good application prospects in the preparation of gene carriers for in vivo treatment. Formula I

The application discloses a cyanobacterial nanogene carrier and a preparation method thereof. By irradiating cyanobacteria under appropriate wavelength light, toxic active oxygen is generated in the cyanobacteria, lysosomes are destroyed, and the gene carrier trapped in the lysosomes is released into the cytoplasm, so that the biological function of the gene can be better exerted, and the problems of the gene carrier in the prior art, such as cationic lipids, cationic polymers, difficult lysosome escape and low gene transfection efficiency, are overcome. Meanwhile, the preparation process is complex, other substances are easily introduced, and the safety is low, and the like are overcome, so that the application is more suitable for efficient delivery of the gene carrier, an effective treatment method is provided for treatment of tumors and the like, and the treatment of cancer and the like is beneficial.

The invention discloses a tannase mutant Tan, a coding gene, a carrier, an engineering bacterium as well as a preparation method and application. The tannase mutant Tan is obtained by mutating amino acids at the 179th site, the 217th site and the 339th site of wild type tannase Tan into leucine, serine and tyrosine from lysine, glutamine and aspartic acid respectively; the amino acid sequence and the nucleotide sequence of the gene are SEQ ID NO.1 and SEQ ID NO.2 respectively. Under the conditions that the pH is 7.0 and the temperature is 50 DEG C, the specific enzyme activity of the tannase mutant Tan is 5268.1 U / mL, which is 1.89 times that of wild enzyme Tan; the residual enzyme activity of the tannase mutant Tan is 4382.9 U / mL and is 2.98 times of the residual enzyme activity of a wild enzyme Tan under the condition of heat preservation for 1 hour at the temperature of 60 DEG C, so that the tannase mutant Tan has an important application prospect under a neutral condition.

The application provides a gene carrier based on a cationic porphyrin covalent organic framework, which is prepared from a porphyrin monomer shown in formula (I) and a cationic monomer shown in formula (II). The application solves the problem that a porphyrin small molecule is prone to aggregation, active oxygen and heat generated are reduced, and the treatment effect is affected by introducing a stable framework structure of a COF. Meanwhile, the COF nanoparticles prepared in the application can carry a gene drug and have a good gene silencing effect. The COF nanoparticles or the COF nanoparticles carrying a gene drug provided in the application can be efficiently accumulated at a tumor site through an EPR effect, and have good photoacoustic imaging, gene therapy and photothermal photodynamic therapy functions, and the gene combined photothermal photodynamic therapy guided by photoacoustic imaging can effectively inhibit the growth of a tumor.

The invention provides a gene for regulating cotton plant height, a recombinant vector and a regulation method, and belongs to the technical field of gene engineering. The invention provides a gene GbGA2ox2f for regulating and controlling the plant height of cotton. The gene GbGA2ox2f comprises a nucleotide sequence as shown in SEQ ID No. 1. It is found that after the expression quantity of the gene GbGA2ox2f is over-expressed in arabidopsis thaliana, the main root length of transgenic arabidopsis thaliana is remarkably shortened, and the plant height is remarkably shortened; after the expression quantity of the gene GbGA2ox2f is reduced in the sea island cotton, the plant height and the active gibberellin content are obviously increased. In addition, the invention finds that the GbKNOX can be specifically combined on the TATTTTTAAAAA site of the GbGA2ox2f promoter. According to the invention, valuable genes, carriers and regulation methods are provided for breeding gossypium barbadense varieties with suitable plant heights, and a foundation is laid for deeply exploring the action mechanism of GbGA2ox2f for regulating the plant heights.